Deal-Making

NorthX Biologics takes over Charles River Swedish plant

NorthX Biologics will take over Charles River’s manufacturing subsidiary Cobra Biologics including its facility in Matfors, Sweden through $52 million acquisition. Seven months on from Charles River Laboratories $875 million acquisition of Cognate Bio (Cognate acquired Cobra Biologics in November 2019) the firm has offloaded one of its Cognate assets, selling a plant in Matfors, Sweden to private investor group Flerie Invest in an acquisition worth $52 million. The entity has been named North X Biologics and the 7,000 square-meter…

Joint research agreement to develop viral vector tech, says Matica Bio

Matica Bio and Sartorius have entered a joint research agreement to develop advanced viral vector manufacturing technology. Matica Biotechnology, a contract development manufacturing organization (CDMO) that specializes in the clinical and commercial production of cell and gene therapies (CGTs), will work on various studies with German life sciences firm Sartorius to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large scale vector production. According to Matica, together both companies will tackle the challenges associated…

Hansoh goes for GOLD in siRNA partnership

Hansoh Pharma will use Silence Therapeutics’ mRNAi GOLD platform to develop three undisclosed short interfering ribonucleic acids (siRNAs). According to RNA interference biotech company Silence, its mRNAi GOLD platform is  “designed to accurately target and ‘silence’ specific disease-associated genes in liver cells by using the body’s natural process of RNA interference (RNAi).” Under the terms of the agreement, Hansoh will have the exclusive option to license rights to two targets in Hong Kong, Greater China, Macau, and Taiwan following Phase…

ISCT partners to provide ‘urgent’ training programs for CGT workforce

The International Society for Cell and Gene Therapy (ISCT) and the National Science Foundation (NSF) have partnered to provide training to upskill personnel. Led by the Georgia Institute of Technology, the global collaboration between ISCT and NSF’s Engineering Research Center for Cell Manufacturing Technologies (CMaT) aims to bridge the critical skills gap in the cell and gene therapy (CGT) industry by delivering educational programs. The joint-training program entitled ‘‘Workforce Development in Biomanufacturing – A Global Partnership with ISCT and CMaT”,…

Terumo and BioCentriq to drive automated CGT manufacturing

BioCentriq’s laboratories will be equipped with Terumo’s technologies to accelerate the adoption of automated production for cell and gene therapies. Apheresis services firm Terumo Blood and Cell Technologies and cell and gene therapy contract development manufacturing organization (CDMO) BioCentriq have entered a strategic collaboration to bring cell and gene therapies (CGT) to individuals more quickly and cheaper. “This agreement will expand customer reach by introducing early-stage CGT researchers and developers to the benefits of manufacturing automation and demonstrating how to…

Aceto buffers up presence in bioprocessing with A&C buy

A&C Bio Buffer is the sixth acquisition for Aceto in the past two years and signals the firm’s ambitions in the biomanufacturing services space. The deal, financials of which have not been disclosed, brings Aceto a GMP (Good Manufacturing Practices) manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products, with a facility in Limerick, Ireland producing over 50 products including biological buffers, process solutions, cleaning solutions and WFI (Water for Injection). “A&C Bio…

Ins and outs: High level changes at BlueRock, Pfizer and the NIH

Emile Nuwaysir has stepped down from his position as CEO of BlueRock and moves to in vivo cell therapy firm Ensoma. Meanwhile, there are changes at Pfizer and the National Institutes of Health (NIH). Nuwaysir has been CEO of Bayer’s subsidiary BlueRock Therapeutics since 2017. Since then, the company has transitioned from a preclinical start-up to a clinical-stage firm that employs over 200 people across two countries. Nuwaysir will remain at the company as a board chair and continue to…

Simulated Bed fellows: Tosoh buys purification firm Semba

Tosoh Bioscience says it will complement its resins business through the addition of continuous chromatography firm Semba Biosciences. The deal, which closed earlier this month, saw Pennsylvania-based Tosoh add all Semba’s staff and assets for an undisclosed fee. The acquisition will boost the firm’s downstream bioproduction portfolio, made up of chromatography resins, with the addition of Semba’s simulated moving bed (SMB) chromatography systems (see text box below). “Coupled with Semba’s revolutionary multi-column chromatography technology we have found a perfect complement…

ViroCell partnership to double UK lentivirus vector capacity

ViroCell has partnered with Great Ormond Street Hospital to address the global viral vector manufacturing bottleneck for clinical trials. Contract development manufacturing organization (CDMO) ViroCell Biologics says its partnership with Great Ormond Street Hospital (GOSH) will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022. Additionally, ViroCell claims the collaboration will secure its position as the first CDMO in the UK to deliver adeno-associated viruses (AAV) vectors to the cell and gene therapy (CGT) markets.…

Gamma invests in bio-sensor and analytics firm Nirrin

Nirrin’s near-infrared spectrometry platform offers a reliable and cost-effective method of real-time analytics and will be leveraged across Gamma’s growing bioprocessing network, the firms says. Gamma Biosciences’s undisclosed investment in Maryland-based Nirrin Technologies brings access to sensors and analytics that support the bioprocess space, including automation tech with real-time, in-process monitoring for upstream and downstream applications. “This is a structured investment with longer term features that allow Nirrin to leverage Gamma’s resources and network in the near term as the…